SciMed Biotech Podcast with David Feltquate of Palleon Pharmaceuticals

The power of glyco-immune checkpoints in cancer treatment

Dive into the future of cancer treatment in this episode of the SciMed Podcast with David Feltquate, Chief Medical Officer at Palleon Pharmaceuticals. 

Discover how David's illustrious career, from heading Oncology Early Clinical Development at Bristol-Myers Squibb to his role as Global Head of Hematology Development at Novartis, has shaped the landscape of cancer research and precision medicine. 

Explore Palleon Pharmaceuticals' pioneering work in developing glyco-immune checkpoint inhibitors, a groundbreaking approach targeting sialic acid to reawaken the immune system's potential to combat cancer. 

David, with his extensive background in oncology, played a pivotal role in the clinical development of the world's first PD-1 inhibitor. He shares insights into this revolutionary journey, from concept to registration in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma. 

With E-602 as their lead drug candidate, designed to desialylate both cancer and immune cells, Palleon Pharmaceuticals is at the forefront of innovation. Learn how they are engineering a brighter future for cancer patients.